Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRENDA MC LATOWSKY

Allopathic & Osteopathic Physicians Dermatology Procedural Dermatology

NPI
1306010467
CMS profile
13863
Location
SCOTTSDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$23,178.11

100 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–100 of 100 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRENDA MC LATOWSKY

NPI 1306010467 · CMS profile ID 13863

Allopathic & Osteopathic Physicians / Dermatology / Procedural Dermatology

SCOTTSDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–100 of 100 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1306010467?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRENDA MC LATOWSKY, NPI 1306010467, CMS profile ID 13863. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–100 of 100 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306010467?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). BRENDA MC LATOWSKY, NPI 1306010467, CMS profile ID 13863. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–100 of 100 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306010467?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
BRENDA MC LATOWSKY, NPI 1306010467, CMS profile ID 13863, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–100 of 100 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1306010467?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

100 matching records · $23,178.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 100 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 100.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $378.0008/25/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997730581 CMS
Dermavant Sciences, Inc. $15.6808/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991215491 CMS
ABBVIE INC. $1,278.0008/18/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997730579 CMS
E.R. Squibb & Sons, L.L.C. $19.7308/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016420011 CMS
ABBVIE INC. $50.2008/10/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997730577 CMS
ABBVIE INC. $28.3608/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087521972 CMS
ABBVIE INC. $8.4507/18/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997730575 CMS
Janssen Biotech, Inc. $21.8807/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988024657 CMS
Axonics, Inc. $22.1707/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051809025 CMS
ABBVIE INC. $102.1606/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997730573 CMS
Galderma Laboratories, L.P. $6.1706/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059710185 CMS
ABBVIE INC. $1,860.2506/19/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997730571 CMS
ABBVIE INC. $182.3006/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997730569 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $28.9706/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996870539 CMS
Galderma Laboratories, L.P. $15.6705/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059710181 CMS
Merz North America, Inc. $19.3805/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050997123 CMS
Merz North America, Inc. $109.2105/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050997127 CMS
Merz North America, Inc. $42.9605/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050997131 CMS
Merz North America, Inc. $62.9805/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050997133 CMS
Merz North America, Inc. $88.5605/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050997137 CMS
MAYNE PHARMA COMMERCIAL LLC $24.4805/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060912261 CMS
Merz North America, Inc. $39.4205/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050997121 CMS
Merz North America, Inc. $135.1705/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050997125 CMS
Merz North America, Inc. $593.7505/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050997129 CMS
Merz North America, Inc. $514.7605/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050997135 CMS
Merz North America, Inc. $190.0105/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050997113 CMS
ABBVIE INC. $89.0005/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997730567 CMS
ABBVIE INC. $8.4505/02/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997730561 CMS
ABBVIE INC. $8.4505/02/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997730563 CMS
ABBVIE INC. $8.4505/02/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997730565 CMS
ABBVIE INC. $26.8504/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997730559 CMS
ABBVIE INC. $88.5004/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997730557 CMS
ABBVIE INC. $125.5504/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997730555 CMS
STRATA Skin Sciences, Inc. $1,400.0003/29/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053061585 CMS
Incyte Corporation $19.8103/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044917227 CMS
ABBVIE INC. $890.0003/17/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997730553 CMS
Merz North America, Inc. $280.3903/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050997139 CMS
ABBVIE INC. $86.0303/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997730551 CMS
Dermavant Sciences, Inc. $24.4503/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991215487 CMS
Merz North America, Inc. $140.2003/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050997115 CMS
ABBVIE INC. $132.6302/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997730549 CMS
Incyte Corporation $24.6402/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044917099 CMS
Amgen Inc. $99.5802/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020545511 CMS
Arcutis Biotherapeutics, Inc. $22.8602/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044661741 CMS
Galderma Laboratories, L.P. $3.1002/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059710179 CMS
ABBVIE INC. $28.7001/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997730547 CMS
E.R. Squibb & Sons, L.L.C. $21.4201/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016419863 CMS
Galderma Laboratories, L.P. $3.7501/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059710175 CMS
Allergan, Inc. $277.9001/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 973113973 CMS
E.R. Squibb & Sons, L.L.C. $19.1201/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016419859 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,449.02 48
PY2020 $7,321.44 43
PY2021 $5,277.57 44
PY2022 $53,128.14 71
PY2023 $23,178.11 100
PY2024 $24,148.97 129
PY2025 $36,783.08 137

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $584,068.28 32
PY2024 Recipient $1,800.00 1
PY2024 Principal investigator $107,854.01 138
PY2023 Principal investigator $275,312.20 115
PY2022 Recipient $136.00 1
PY2022 Principal investigator $1,102,786.02 70
PY2021 Recipient $200.00 1
PY2021 Principal investigator $335,050.25 54
PY2020 Recipient $3,549.00 1
PY2020 Principal investigator $570,904.87 79
PY2019 Recipient $13,343.75 2
PY2019 Principal investigator $530,113.82 40

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $2,177.82 12/31/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A Phase 1 Study to Evaluate the Safety and Efficacy of Co-administration of AGN-151586 and BOTOX in Subjects for Treatment of Glabellar Lines (GL) No dispute reported 06/30/2026 1202534787
Principal investigator 1 ABBVIE INC. $2,437.50 12/11/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System No dispute reported 06/30/2026 1202529984
Principal investigator 1 ABBVIE INC. $28,429.60 12/04/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202526586
Principal investigator 1 ABBVIE INC. $35,724.00 11/17/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System No dispute reported 06/30/2026 1202524435
Principal investigator 1 Galderma Laboratories, L.P. $1,800.00 11/12/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234517511
Principal investigator 1 ABBVIE INC. $21,740.55 11/05/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202521749
Principal investigator 1 Galderma Laboratories, L.P. $21,434.05 10/17/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234517318
Principal investigator 1 ABBVIE INC. $31,072.80 10/09/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202514617
Principal investigator 1 ABBVIE INC. $8,879.00 10/09/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System No dispute reported 06/30/2026 1202514619
Principal investigator 1 ABBVIE INC. $1,536.50 10/09/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202514621
Principal investigator 1 ABBVIE INC. $97,294.50 09/04/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202509218
Principal investigator 1 ABBVIE INC. $1,536.50 09/03/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202507827
Principal investigator 1 ABBVIE INC. $147,752.55 08/06/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202503453
Principal investigator 1 Galderma Laboratories, L.P. $180.00 08/05/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234515578
Principal investigator 1 Galderma Laboratories, L.P. $1,800.11 07/18/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234515339
Principal investigator 1 Galderma Laboratories, L.P. $11,386.12 07/09/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234515282
Principal investigator 1 ABBVIE INC. $79,880.55 07/08/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202497176
Principal investigator 1 ABBVIE INC. $5,000.00 07/02/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202494907
Principal investigator 1 Galderma Laboratories, L.P. $9,411.70 06/20/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234515059
Principal investigator 1 Galderma Laboratories, L.P. $14,400.90 06/03/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234514871
Principal investigator 1 Galderma Laboratories, L.P. $12,023.98 05/15/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234514686
Principal investigator 1 ABBVIE INC. $1,466.60 05/07/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202483993
Principal investigator 1 ABBVIE INC. $1,198.40 05/06/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202482229
Principal investigator 1 ABBVIE INC. $1,198.40 04/03/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202470133
Principal investigator 1 Galderma Laboratories, L.P. $23,909.62 03/31/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234513991
Principal investigator 1 ABBVIE INC. $2,881.90 03/07/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202461298
Principal investigator 1 Galderma Laboratories, L.P. $7,066.12 03/03/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234513519
Principal investigator 1 Galderma Laboratories, L.P. $1,582.86 02/14/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies No dispute reported 06/30/2026 1234513278
Principal investigator 1 ABBVIE INC. $305.70 02/05/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202444463
Principal investigator 1 Eli Lilly and Company $6,754.95 01/15/2025 Non-covered Recipient Entity
INVESTIGATE MD, LLC
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187882184
Principal investigator 1 ABBVIE INC. $389.70 01/02/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202434121
Principal investigator 1 ABBVIE INC. $1,415.30 01/02/2025 Non-covered Recipient Entity
INVESTIGATE MD LLC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202434125